The following is a summary of the Xtant Medical Holdings Inc. (XTNT) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Xtant Medical Holdings saw Q4 revenue of $28.1 million, an 84% increase year-over-year.

• The Company reported annual revenue growth of more than 58% in 2023 with full year revenue of $91.3 million.

• Generated positive EBITDA continually for the last three quarters.

• The Financial Year 2023 saw adjusted organic growth of 17%.

• Margins improved by 540 basis points through operational efficiencies and product mix.

• The company experienced a Q4 2023 net loss of $4.3 million or $0.03 per share.

• Extended its revolving credit facility with MidCap Financial to $17 million from $8 million for growth initiatives.

Business Progress:

• Made significant headway having acquired three businesses in 2023.

• Operational capabilities were enhanced, improving clean room capacity by over 50%.

• The Company expanded its biologics product offering from two product categories to five.

• Distribution network expansion, now boasting over 650 independent agents.

• The acquisitions of Surgalign and Coflex bolstered Xtant's fixation line and operations on the ambulatory surgery centers and outpatient markets.

• Implementation of crucial process improvement initiatives and capacity expansion has resulted in increased production levels and efficiency.

• Focused on capturing a greater share of the spine and orthobiologics market.

• Forecasted a full year 2024 revenue range of $112 million to $116 million, representing revenue growth of approximately 23% to 27% compared to the full year 2023.

More details: Xtant Medical IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.